

Anthony D D'urzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8512830/publications.pdf>

Version: 2024-02-01

33
papers

894
citations

687335

13
h-index

454934

30
g-index

33
all docs

33
docs citations

33
times ranked

768
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical knowledge about COVID-19 is travelling at the speed of mistrust: why this is relevant to primary care. <i>Family Practice</i> , 2022, 39, 988-991.	1.9	3
2	Acclidinium bromide/formoterol fumarate as a treatment for COPD: an update. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1093-1106.	2.5	3
3	Variation Among Spirometry Interpretation Algorithms. <i>Respiratory Care</i> , 2020, 65, 1585-1590.	1.6	5
4	Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. <i>Respiratory Research</i> , 2019, 20, 141.	3.6	18
5	Prevalence and Characteristics of Asthmaâ€“Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1143-1150.	3.2	32
6	Acclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 1753466661985072.	2.6	4
7	<p>Efficacy of acclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT<p>. <i>International Journal of COPD</i> , 2019, Volume 14, 479-491.	2.3	7
8	Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. <i>Pulmonary Therapy</i> , 2019, 5, 23-41.	2.2	7
9	<p>An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-NaÃ“ve Patients With COPD<p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2835-2848.	2.3	16
10	FEV₁ reversibility for asthma diagnosis: a critical evaluation. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 265-267.	2.5	11
11	Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials. <i>Npj Primary Care Respiratory Medicine</i> , 2018, 28, 18.	2.6	8
12	Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 1089-1104.	2.3	6
13	Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of acclidinium plus formoterol in COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 13.	2.6	3
14	A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of acclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2017, 125, 39-48.	2.9	28
15	Reduction in clinically important deterioration in chronic obstructive pulmonary disease with acclidinium/formoterol. <i>Respiratory Research</i> , 2017, 18, 106.	3.6	30
16	Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. <i>Respiratory Research</i> , 2016, 17, 112.	3.6	48
17	Acclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and) Tj ETQq1 1 0.784314 rgBT2 Over	1.0	1
18	Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. <i>International Journal of COPD</i> , 2015, 10, 1599.	2.3	19

#	ARTICLE	IF	CITATIONS
19	A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1845-1860.	1.8	30
20	Differences in spirometry interpretation algorithms: influence on decision making among primary-care physicians. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15008.	2.6	7
21	Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. <i>Respiratory Research</i> , 2014, 15, 123.	3.6	130
22	Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. <i>Current Medical Research and Opinion</i> , 2014, 30, 493-508.	1.9	31
23	Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. <i>European Respiratory Journal</i> , 2014, 43, 1599-1609.	6.7	137
24	The challenge of objective confirmation of asthma diagnosis in primary care. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14032.	2.6	6
25	Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 341.	2.0	4
26	Future of chronic obstructive pulmonary disease management. <i>Expert Review of Respiratory Medicine</i> , 2012, 6, 285-299.	2.5	9
27	Four-year trial of tiotropium in chronic obstructive pulmonary disease. <i>Canadian Family Physician</i> , 2012, 58, 848-9.	0.4	0
28	Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. <i>Respiratory Research</i> , 2011, 12, 156.	3.6	162
29	New spirometry interpretation algorithm: Primary Care Respiratory Alliance of Canada approach. <i>Canadian Family Physician</i> , 2011, 57, 1148-52.	0.4	9
30	Limitations of a spirometry interpretation algorithm. <i>Canadian Family Physician</i> , 2011, 57, 1153-6.	0.4	5
31	Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective. <i>Canadian Family Physician</i> , 2010, 56, 119-20, 123-4.	0.4	1
32	Must family physicians use spirometry in managing asthma patients?: NO. <i>Canadian Family Physician</i> , 2010, 56, 127, 129, 131, 133; discussion e50, e52.	0.4	7
33	Inhaled Glucocorticosteroid and Long-Acting ??2-Adrenoceptor Agonist Single-Inhaler Combination for Both Maintenance and Rescue Therapy. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 385-391.	1.4	6